Bitget App
Trade smarter
MarketsTradeFuturesEarnAISquareMore
Kashiv Biosciences has agreed to be acquired by Amneal Pharmaceuticals, aiming to create a fully integrated global leader in biosimilars.

Kashiv Biosciences has agreed to be acquired by Amneal Pharmaceuticals, aiming to create a fully integrated global leader in biosimilars.

老虎证券老虎证券2026/04/22 10:23
Show original
The transaction will integrate both parties’ advantageous resources in R&D, production, and commercialization to form a strong synergy. Through this strategic merger, the new entity will possess capabilities spanning the entire value chain of biosimilars—from early-stage development to global marketing—further strengthening its competitiveness in the rapidly growing biopharmaceutical market. Market observers believe this integration will reshape the industry landscape and provide patients with more affordable, high-quality treatment options. The financial details and specific timeline of the transaction have not yet been disclosed, and completion is expected after the customary closing conditions are met. Both management teams are optimistic about the merged entity’s prospects, believing this will accelerate access to innovative therapies and create long-term sustainable value.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Federal Reserve's Kashkari: US Treasury market continues to operate normally; rising yields do not affect monetary policy discussions

Minneapolis Federal Reserve President Neel Kashkari downplayed concerns over the rising yields of U.S. Treasury bonds, stating that the market is functioning well and the recent surge in yields is unlikely to affect monetary policy discussions.

智通财经2026/08/24 00:01
Federal Reserve's Kashkari: US Treasury market continues to operate normally; rising yields do not affect monetary policy discussions